Myeloablative allogeneic stem cell transplant for AML and MDS: the impact of advanced age in the outcome

被引：0
|
作者：
Sanchez-Escamilla, M. [1 ,2 ]
Garcia-Avila, S. [1 ]
Yanez San Segundo, L. [1 ,2 ]
Bermudez Rodriguez, M. A. [1 ,2 ]
Colorado Araujo, M. M. [1 ,2 ]
Casado Diez, A. [1 ]
Celis Alvarez, M. [1 ]
Cabero Martinez, A. [1 ]
Fernandez Martinez, C. [1 ]
Insunza Garminde, A. [1 ,2 ]
Richard Espiga, C. [1 ,2 ]
Conde Garcia, E. [1 ,2 ]
机构：
[1] Marques de Valdecilla Univ Hosp, Santander, Spain
[2] IDIVAL, Santander, Spain
来源：
BONE MARROW TRANSPLANTATION | 2017年 / 52卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P415
引用
收藏
页码：S333 / S334
页数：2
相关论文
共 50 条
  • [41] Comparison of Transplant Outcomes and Economic Costs in Allogeneic Stem Cell Transplantation for AML and MDS Between The Different Type of Donors
    Gonzalez Romero, Yolanda
    Manuel Mora, Joan
    Fernandez-Luis, Sara
    Gomez-Lamas, David
    Calvo-Sanchez, Jose
    Fernandez-Garcia, Sergio
    Luis Arroyo, Jose
    Bermudez, Aranzazu
    Ocio, Enrique
    Yanez, Lucrecia
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 673 - 674
  • [42] Reduced toxicity myeloablative conditioning regimens compared with standard myeloablative conditioning prior to allogeneic stem cell transplantation in AML and MDS; more favourable toxicity profile but more limited leukaemia control in advanced disease
    Shimoni, A.
    Rand, A.
    Shem-Tov, N.
    Volchek, Y.
    Yerushalmi, R.
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S46 - S47
  • [43] Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity
    A Shimoni
    I Hardan
    N Shem-Tov
    M Yeshurun
    R Yerushalmi
    A Avigdor
    I Ben-Bassat
    A Nagler
    Leukemia, 2006, 20 : 322 - 328
  • [44] Impact of cytogenetics and prior therapy on outcome of AML and MDS after allogeneic transplantation.
    Armand, Philippe
    Kim, Haesook T.
    DeAngelo, Daniel J.
    Ho, Vincent T.
    Cutler, Corey S.
    Stone, Richard M.
    Ritz, Jerome
    Alyea, Edwin P.
    Antin, Joseph H.
    Soiffer, Robert J.
    BLOOD, 2006, 108 (11) : 80A - 81A
  • [45] Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced intensity conditioning: The role of dose-intensity.
    Shimoni, A
    Hardan, I
    Shem-Tov, N
    Yeshurun, M
    Yerushalmi, R
    Ben-Bassat, I
    Nagler, A
    BLOOD, 2005, 106 (11) : 18A - 19A
  • [46] Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS
    Alatrash, Gheath
    Kidwell, Kelly M.
    Thall, Peter F.
    Di Stasi, Antonio
    Chen, Julianne
    Zope, Madhushree
    Crain, Alyssa K.
    Champlin, Richard E.
    Popat, Uday
    Shpall, Elizabeth J.
    Jones, Roy B.
    Andersson, Borje S.
    BONE MARROW TRANSPLANTATION, 2019, 54 (08) : 1245 - 1253
  • [47] Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS
    Gheath Alatrash
    Kelly M. Kidwell
    Peter F. Thall
    Antonio Di Stasi
    Julianne Chen
    Madhushree Zope
    Alyssa K. Crain
    Richard E. Champlin
    Uday Popat
    Elizabeth J. Shpall
    Roy B. Jones
    Borje S. Andersson
    Bone Marrow Transplantation, 2019, 54 : 1245 - 1253
  • [48] Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity
    Shimoni, A
    Hardan, I
    Shem-Tov, N
    Yeshurun, M
    Yerushalmi, R
    Avigdor, A
    Ben-Bassat, I
    Nagler, A
    LEUKEMIA, 2006, 20 (02) : 322 - 328
  • [49] Fludarabine and treosulfan conditioning for allogeneic stem cell transplantation (SCT) in patients with AML and MDS not eligible for standard myeloablative conditioning: the role of treosulfan dose
    Shimoni, A.
    Peccatori, J.
    Shem-Tov, N.
    Lo Russo, A.
    Yerushalmi, R.
    Bernardi, M.
    Nagler, A.
    Ciceri, F.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S220 - S220
  • [50] Disease status at transplant impacts lymphocyte and platelet recovery after allogeneic peripheral blood stem cell transplant (PBSCT) for patients with AML/MDS
    Salibu, RM
    Oran, B
    Giralt, S
    Komanduri, K
    Carrasco-Yalan, A
    Ghosh, S
    Champlin, R
    de Lima, M
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 42 - 42
12345